Skip to main content
. Author manuscript; available in PMC: 2018 May 3.
Published in final edited form as: Nature. 2017 Nov 1;551(7679):247–250. doi: 10.1038/nature24297

Figure 2. Persister cells are vulnerable to GPX4 inhibition.

Figure 2

Breast (BT474), melanoma (A375), lung (PC9) and ovarian (Kuramochi) cancer parental or persister cells (see Methods) were treated with GPX4 inhibitor RSL3 (a-d) or ML210 (e-h) for three days. i, A375 GPX4 WT or KO persister cells and j, parental cells with ferrostatin-1 withdrawn for three days. Data are plotted as means and error bars represent standard deviation. a-h, n = 2, and i, j, n = 3 biologically independent samples. From two-tailed t tests,*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, P > 0.05. All data are representative of two separate experiments.